TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27642534

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (a combination of aerobic, resistance, and flexibility exercises, average of 2.5 hours a week)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 43
Study: 27642538

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.02 mg/kg BID at Week 1, 0.04 mg/kg BID at Week 2, maximum 0.08 mg/kg BID thereafter)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 23
Study: 27642657

Group type: EXPERIMENTAL
Intervention: Shock anticipation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear-potentiated startle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat-related/task-unrelated thoughts
Number of subjects: 0
Study: 27643438

Group type: EXPERIMENTAL
Intervention: WASP-deficient Tregs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional deletion of Was in FOXP3+ Tregs
Number of subjects: 0
Study: 27643485

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg, two infusions
Number of subjects: 24
Study: 27644174

Group type: EXPERIMENTAL
Intervention: Advanced dental maturity group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Delayed and average dental maturity groups
Number of subjects: 111
Study: 27644469

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections
Number of subjects: 3414
Study: 27644734

Group type: EXPERIMENTAL
Intervention: Fecal gluten immunogenic peptides (GIP) measured by ELISA
Number of subjects: 188

Group type: COMPARATOR
Intervention: Dietary questionnaire
Number of subjects: 188

Group type: COMPARATOR
Intervention: Anti-tissue transglutaminase (anti-tTG) IgA antibodies
Number of subjects: 188

Group type: COMPARATOR
Intervention: Anti-deamidated gliadin peptide (anti-DGP) IgA antibodies
Number of subjects: 188
Study: 27645461

Group type: EXPERIMENTAL
Intervention: Eotaxin levels
Number of subjects: 27
Study: 27646946

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks
Number of subjects: 132
Study: 27647056

Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 1528
Study: 27647168

Group type: EXPERIMENTAL
Intervention: NOACs (Novel Oral Anticoagulants)
Number of subjects: 39670

Group type: COMPARATOR
Intervention: VKA±AP (Vitamin K Antagonists plus Antiplatelet) or AP (Antiplatelet) alone
Number of subjects: 39670
Study: 27647694

Group type: EXPERIMENTAL
Intervention: Insular infarction
Number of subjects: 736

Group type: COMPARATOR
Intervention: No insular infarction
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Right insular infarction
Number of subjects: 736
Study: 27647864

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg, days 1-21/28 days) + continuous cyclophosphamide (50 mg/d) + prednisone (20 mg/d)
Number of subjects: 67
Study: 27648287

Group type: EXPERIMENTAL
Intervention: Higher baseline fitness (measured by treadmill duration)
Number of subjects: 3358

Group type: COMPARATOR
Intervention: Modified Mediterranean diet pattern
Number of subjects: 3358
Study: 27648286

Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during URTI
Number of subjects: 20
Study: 27648290

Group type: EXPERIMENTAL
Intervention: Diabetes-specific oral nutritional supplement (ONS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard oral nutritional supplement (ONS)
Number of subjects: 12
Study: 27648294

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² on day 1 and capecitabine 900 mg/m² two times per day from day 1 to day 14 every 3 weeks (2 cycles)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Docetaxel and capecitabine
Number of subjects: 18
Study: 27648659

Group type: EXPERIMENTAL
Intervention: Estradiol levels in women with AHI ≥15 (moderate-to-severe OSA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher estradiol levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Estradiol levels after adjusting for age and BMI
Number of subjects: 30
Study: 27649801

Group type: EXPERIMENTAL
Intervention: Infant BMI peak characteristics
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Infant BMI peak
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Age at peak BMI
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Peak magnitude
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Older age and higher magnitude at peak
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Ethnic-specific differences in BMI peak characteristics
Number of subjects: 1020
Study: 27649927

Group type: EXPERIMENTAL
Intervention: Perifosine 50-75 mg
Number of subjects: 0
Study: 27650225

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24mcg b.i.d., P.O. for 2 weeks)
Number of subjects: 29
Study: 27650271

Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst ablation (PCA) with ethanol alone (n=8) or ethanol and paclitaxel (n=28)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst ablation (PCA)
Number of subjects: 36
Study: 27650284

Group type: EXPERIMENTAL
Intervention: Real-time US-CT/MR fusion imaging guidance
Number of subjects: 216

Group type: COMPARATOR
Intervention: B-mode US
Number of subjects: 216
Study: 27650283

Group type: EXPERIMENTAL
Intervention: SHBs mutants with amino acid substitutions
Number of subjects: 230

Group type: COMPARATOR
Intervention: Wild-type HBsAg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Untreated CHB patients with novel SHBs mutations
Number of subjects: 230
Study: 27650822

Group type: EXPERIMENTAL
Intervention: Early β blockers (≤48 hours of admission)
Number of subjects: 2679

Group type: EXPERIMENTAL
Intervention: β blockers at discharge
Number of subjects: 2679

Group type: EXPERIMENTAL
Intervention: Persistence of β blockers at one year
Number of subjects: 2679

Group type: EXPERIMENTAL
Intervention: Continuing statins at one year
Number of subjects: 2679
Study: 27651231

Group type: EXPERIMENTAL
Intervention: ROP telemedicine evaluation system
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Image sets submitted before 2 p.m. EST
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Image sets submitted after 2 p.m. EST
Number of subjects: 292
Study: 27651304

Group type: EXPERIMENTAL
Intervention: Personal fitness tracker (PFT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulse oximetry (Spo2.R)
Number of subjects: 50
Study: 27651390

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Stroke
Number of subjects: 1166
Study: 27651793

Group type: EXPERIMENTAL
Intervention: DM-1 group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 42
Study: 27651909

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) containing fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27652031

Group type: EXPERIMENTAL
Intervention: Concentric exercise (CE)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (EE)
Number of subjects: 7
Study: 27652248

Group type: EXPERIMENTAL
Intervention: Parental presence (fathers)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Parental presence (mothers)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No parental presence
Number of subjects: 122
Study: 27652687

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Navigated computer-assisted surgery (CAS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional TKA surgical techniques
Number of subjects: 128
Study: 27653085

Group type: EXPERIMENTAL
Intervention: MedGem (MG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard indirect calorimeter (VMax)
Number of subjects: 54

Group type: COMPARATOR
Intervention: MedGem (MG) vs VMax
Number of subjects: 54
Study: 27653529

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b therapy
Number of subjects: 445
Study: 27653565

Group type: EXPERIMENTAL
Intervention: KAF156 multiple doses (400 mg once daily for 3 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: KAF156 single dose (800 mg)
Number of subjects: 41
Study: 27653771

Group type: EXPERIMENTAL
Intervention: Single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Post-challenge adverse events (AEs) monitoring
Number of subjects: 300
Study: 27654119

Group type: EXPERIMENTAL
Intervention: GooDMomS program (web-based intervention)
Number of subjects: 23
Study: 27654603

Group type: EXPERIMENTAL
Intervention: Non-TNF-targeted biologic
Number of subjects: 300

Group type: COMPARATOR
Intervention: Second anti-TNF drug
Number of subjects: 300
Study: 27654882

Group type: EXPERIMENTAL
Intervention: Niacin 500 mg q1h for 4 doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niacin 500 mg q2h for 3 doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niacin 250 mg q2h for 3 doses
Number of subjects: 12
Study: 27654985

Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride (15 mg twice daily) with sevelamer carbonate (800 mg 3 times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenapanor hydrochloride (15 mg twice daily) without sevelamer carbonate
Number of subjects: 0
Study: 27655115

Group type: EXPERIMENTAL
Intervention: Home-based structured exercise (sitting Tai Chi)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Social contact control
Number of subjects: 272
Study: 27655184

Group type: EXPERIMENTAL
Intervention: Paid Facebook advertisements
Number of subjects: 115

Group type: COMPARATOR
Intervention: Traditional recruitment approaches
Number of subjects: 115
Study: 27655260

Group type: EXPERIMENTAL
Intervention: History of falls in the 6 months prior to surgery
Number of subjects: 0
Study: 27655442

Group type: EXPERIMENTAL
Intervention: Higher maternal plasma betaine
Number of subjects: 955
Study: 27655463

Group type: EXPERIMENTAL
Intervention: Long sleepers (≥ 8 h)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Normal sleepers (6-8 h)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Short sleepers (< 6 h)
Number of subjects: 500
Study: 27656000

Group type: EXPERIMENTAL
Intervention: Change in LVEF by ≥5 U (improvement)
Number of subjects: 2484

Group type: COMPARATOR
Intervention: Change in LVEF
Number of subjects: 2484
Study: 27656788

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg, administered over 100min) during acute-phase treatment (up to 6 thrice-weekly infusions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuation-phase treatment with 4 weekly ketamine infusions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-continuation phase follow-up (4 weeks, no further ketamine infusions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acute-phase and continuation-phase treatment
Number of subjects: 12
Study: 27656840

Group type: EXPERIMENTAL
Intervention: Low-protein diet for 12 months
Number of subjects: 7
Study: 27657052

Group type: EXPERIMENTAL
Intervention: Smokers with mild to moderate COPD (GOLD stages 1 and 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 0
Study: 27657348

Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (Rotarix™)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study: 27657493

Group type: EXPERIMENTAL
Intervention: MRI with liver-specific contrast
Number of subjects: 407

Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Patients with HCC
Number of subjects: 407
Study: 27657681

Group type: EXPERIMENTAL
Intervention: Migalastat treatment
Number of subjects: 51
Study: 27657899

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 18
Study: 27658437

Group type: COMPARATOR
Intervention: miR-150-5p
Number of subjects: 41

Group type: COMPARATOR
Intervention: miR-146b-5p
Number of subjects: 41

Group type: COMPARATOR
Intervention: miR-1
Number of subjects: 41

Group type: COMPARATOR
Intervention: Logistic model with 3 microRNAs
Number of subjects: 41
Study: 27658471

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT) via duodenal route (44.4%), colonic (41.1%), capsule (9.8%), gastric (3.0%)
Number of subjects: 133
Study: 27658581

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27658740

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg daily for 12 weeks
Number of subjects: 17
Study: 27658757

Group type: EXPERIMENTAL
Intervention: Higher than normal range of BUN/creatinine ratio
Number of subjects: 2033
Study: 27658863

Group type: EXPERIMENTAL
Intervention: Vacc-4x (12 mg/mL) and rhuGM-CSF (0.6 mg/mL) administered intradermally over 12 weeks followed by romidepsin (5 mg/m2) intravenously once a week for 3 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Romidepsin treatment (5 mg/m2) administered intravenously once a week for 3 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vacc-4x and rhuGM-CSF followed by romidepsin treatment.
Number of subjects: 20
Study: 27658864

Group type: EXPERIMENTAL
Intervention: 1200 mg long-acting rilpivirine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 600 mg long-acting rilpivirine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: long-acting rilpivirine
Number of subjects: 36
Study: 27658870

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) taken as one tablet per day for a median of 72 weeks
Number of subjects: 1224
Study: 27658906

Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE) features
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VLE neoplasia prediction score
Number of subjects: 25
Study: 27658980

Group type: EXPERIMENTAL
Intervention: Acute leukoencephalopathy during chemotherapy treatment
Number of subjects: 190
Study: 27659464

Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: First NGAL
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: First NGAL <150 ng/ml
Number of subjects: 927
Study: 27659897

Group type: EXPERIMENTAL
Intervention: Telephone consultation based on a protocol (formal Telephone Medical Advice - fTMA)
Number of subjects: 2880

Group type: COMPARATOR
Intervention: Usual handling of calls by call centre physician
Number of subjects: 2880
Study: 27660108

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) detected in CMR
Number of subjects: 20
Study: 27660125

Group type: EXPERIMENTAL
Intervention: Regular exercise commenced in early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study: 27660316

Group type: EXPERIMENTAL
Intervention: I-Preventive (digital preventive tool)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study: 27660322

Group type: EXPERIMENTAL
Intervention: Peer Comparison (PC)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Accountable Justifications (JA)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Suggested Alternatives (SA)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Pay-for-performance
Number of subjects: 234

Group type: COMPARATOR
Intervention: Additional clinic time
Number of subjects: 234
Study: 27660515

Group type: EXPERIMENTAL
Intervention: Patients with <10 pack-years of smoking history
Number of subjects: 203

Group type: COMPARATOR
Intervention: Patients with ≥10 pack-years of smoking history
Number of subjects: 203
Study: 27660663

Group type: EXPERIMENTAL
Intervention: Twice-daily insulin lispro low mixture (LM25)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL)
Number of subjects: 162
Study: 27661411

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 22
Study: 27662790

Group type: EXPERIMENTAL
Intervention: Good movement quality group (n=19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Moderate movement quality group (n=20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Poor movement quality group (n=20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison between good and poor movement quality groups
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Correlation between ankle dorsiflexion ROM and Lateral Step Down Test scores
Number of subjects: 59
Study: 27663201

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID plus background methotrexate (ORAL Scan)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID as monotherapy (ORAL Start)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1600
Study: 27663508

Group type: EXPERIMENTAL
Intervention: Interactive Computer-Assisted Client Assessment Survey (iCCAS)
Number of subjects: 74
Study: 27663515

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus radiotherapy
Number of subjects: 1
Study: 27663759

Group type: EXPERIMENTAL
Intervention: Zoledronate + HSRT (3 × 9 Gy)
Number of subjects: 30
Study: 27663950

Group type: EXPERIMENTAL
Intervention: Training interventions after first training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Training interventions after further training
Number of subjects: 22
Study: 27664062

Group type: EXPERIMENTAL
Intervention: Gla-300 (insulin glargine 300 U/mL)
Number of subjects: 40
Study: 27664171

Group type: EXPERIMENTAL
Intervention: Trained non-nursing staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Certified Nursing Assistants (CNAs)
Number of subjects: 0
Study: 27664804

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Injection of glycine and kynurenine alone or in combination
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 27666002

Group type: EXPERIMENTAL
Intervention: Pre-treatment with ticagrelor (at least 1.5h before PCI)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control Group (ticagrelor administered immediately before PCI)
Number of subjects: 143
Study: 27667713

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs-TnT) measured at 48 hours after return of spontaneous circulation (ROSC)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs-TnT) in patients with STEMI at 48 hours after ROSC
Number of subjects: 699

Group type: COMPARATOR
Intervention: Targeted temperature management at 33°C
Number of subjects: 699
Study: 27667752

Group type: EXPERIMENTAL
Intervention: Rhinovirus/enterovirus
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Parainfluenza
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Coronavirus
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Human metapneumovirus
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Human bocavirus (HBov)
Number of subjects: 6266
Study: 27668024

Group type: EXPERIMENTAL
Intervention: Effervescent NAC tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral solution NAC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study: 27669017

Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (IIV-HD)
Number of subjects: 32000

Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine (SD)
Number of subjects: 32000
Study: 27669027

Group type: EXPERIMENTAL
Intervention: Genetic associations with emphysema distribution
Number of subjects: 11532

Group type: EXPERIMENTAL
Intervention: Gene set analysis and in silico functional evaluation
Number of subjects: 11532
Study: 27669153

Group type: EXPERIMENTAL
Intervention: Four-month individualized resistance training intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (non-frail, maternal BMI ≤ 26.3 kg/m2)
Number of subjects: 37
Study: 27669747

Group type: EXPERIMENTAL
Intervention: FPG target ≤5.6 mmol/L
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: FPG target ≤6.1 mmol/L
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: FPG target ≤7.0 mmol/L
Number of subjects: 934
Study: 27670515

Group type: EXPERIMENTAL
Intervention: Intervention group (salt reduction education); duration: 3.5 months.
Number of subjects: 832

Group type: COMPARATOR
Intervention: Control group (no intervention); duration: 3.5 months.
Number of subjects: 832
Study: 27670519

Group type: EXPERIMENTAL
Intervention: Behavioural Couples Therapy (BCT) involving the gambler and the CSO
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cognitive-Behavioural Therapy (CBT) involving the gambler alone
Number of subjects: 120
Study: 27671037

Group type: EXPERIMENTAL
Intervention: Value-based formulary which eliminates copayment for high-value preventive medications
Number of subjects: 4714

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management support program promoting health behavior change and medication adherence
Number of subjects: 4714

Group type: EXPERIMENTAL
Intervention: Combination of value-based formulary and self-management support program
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4714
Study: 27671742

Group type: EXPERIMENTAL
Intervention: EMOTION Coping Kids Managing Anxiety and Depression (EMOTION)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36
Study: 27671901

Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with high vascular risk (37.2%)
Number of subjects: 2909

Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with medium vascular risk (15.1%)
Number of subjects: 2909

Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with low vascular risk (6.5%)
Number of subjects: 2909

Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with established cardiovascular disease (CVD) (75.3%)
Number of subjects: 2909

Group type: COMPARATOR
Intervention: Increasing vascular risk and CVD
Number of subjects: 2909